Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1982 1
1989 1
1996 1
2000 1
2001 1
2003 1
2006 1
2008 1
2010 2
2011 4
2012 3
2013 1
2014 1
2015 2
2016 1
2017 2
2018 1
2019 2
2020 3
2021 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

30 results
Results by year
Filters applied: . Clear all
Page 1
Mechanisms of Action of the KCa2-Negative Modulator AP30663, a Novel Compound in Development for Treatment of Atrial Fibrillation in Man.
Bentzen BH, Bomholtz SH, Simó-Vicens R, Folkersen L, Abildgaard L, Speerschneider T, Muthukumarasamy KM, Edvardsson N, Sørensen US, Grunnet M, Diness JG. Bentzen BH, et al. Among authors: sorensen us. Front Pharmacol. 2020 May 6;11:610. doi: 10.3389/fphar.2020.00610. eCollection 2020. Front Pharmacol. 2020. PMID: 32477117 Free PMC article.
pH-dependent inhibition of K₂P3.1 prolongs atrial refractoriness in whole hearts.
Skarsfeldt MA, Jepps TA, Bomholtz SH, Abildgaard L, Sørensen US, Gregers E, Svendsen JH, Diness JG, Grunnet M, Schmitt N, Olesen SP, Bentzen BH. Skarsfeldt MA, et al. Among authors: sorensen us. Pflugers Arch. 2016 Apr;468(4):643-54. doi: 10.1007/s00424-015-1779-0. Epub 2016 Jan 5. Pflugers Arch. 2016. PMID: 26729267
The KCa2 Channel Inhibitor AP30663 Selectively Increases Atrial Refractoriness, Converts Vernakalant-Resistant Atrial Fibrillation and Prevents Its Reinduction in Conscious Pigs.
Diness JG, Kirchhoff JE, Speerschneider T, Abildgaard L, Edvardsson N, Sørensen US, Grunnet M, Bentzen BH. Diness JG, et al. Among authors: sorensen us. Front Pharmacol. 2020 Feb 28;11:159. doi: 10.3389/fphar.2020.00159. eCollection 2020. Front Pharmacol. 2020. PMID: 32180722 Free PMC article.
30 results